31 results about "Deacetylase activity" patented technology

The acetylation level of a peptide is determined utilizing the fact that the changes in the acetylation level are reflected in the sensitivity of the substrate peptide to a peptidase. This method can be used for measuring activities of deacetylase and acetylase, and also enables screening for substances that influence the activity of these enzymes. The deacetylase activity can be measured by a simple procedure according to the present invention.

The acetylation level of a peptide is determined utilizing the fact that the changes in the acetylation level are reflected in the sensitivity of the substrate peptide to a peptidase. This method can be used for measuring activities of deacetylase and acetylase, and also enables screening for substances that influence the activity of these enzymes. The deacetylase activity can be measured by a simple procedure according to the present invention.

The present invention provides treatment methods involving modulating a sirtuin activity and / or a sirtuin mRNA and / or a sirtuin polypeptide level. In some embodiments, the present invention provides treatment methods involving modulating SIRT1 activity and / or SIRT mRNA and / or polypeptide level. The present invention provides methods of inhibiting SIRT1 Tat deacetylase activity. Methods of inhibiting SIRT1 Tat deacetylase activity are useful for treating immunodeficiency virus infections, particularly human immunodeficiency virus (HIV) infection. Thus, the present invention provides methods of treating an immunodeficiency virus infection, generally involving inhibiting SIRT1 Tat deacetylase activity. The present invention further provides methods of identifying agents that modulate sirtuin activity (e.g., SIRT1 activity), particularly ability of sirtuins to interact with (e.g., bind and / or deacetylate) a substrate, e.g., a viral substrate such as a Tat polypeptide. The present invention further provides active agents that modulate sirtuin activity or expression; and compositions, including pharmaceutical compositions, comprising the active agents.

The identification and cloning of histone deacetylase 9 (HDAC9) is disclosed, and in particular full length HCAC9 polypeptides and HDAC9 polypeptides which have deacetylase activity, and to nucleic acid molecules encoding these polypeptides. The uses of these polypeptides and nucleic acid molecules are disclosed, for example for screening for compounds that are capable of modulating HDAC9 biological activity.

HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase / deacetylase activity as described herein (e.g., cancer). In certain embodiments, the compounds of the invention selectively target either a class or isoform of the HDAC family. Another aspect of the invention provides an assay for determining the inhibitory effect of a test compound on an HDAC protein comprising: incubating the HDAC protein with a substrate of general formula (IIIc) in the presence of a test compound; and determining the activity of the HDAC protein.

A method for simply and conveniently detecting acetyltransferase and deacetylase activities of proteins by executing an acetylation reaction of a peptide substrate with an acetyltransferase, or a deacetylation reaction of an acetylated peptide substrate with a deacetylase, and after the completion of these reactions, detecting the acetyl group bound to the peptide substrate by using an anti-acetylated peptide antibody. This system for detecting acetyltransferase and deacetylase activities using the anti-acetylated peptide antibody enables screening inhibitors or enhancers of acetyltransferase and deacetylase. A system for screening deacetylase inhibitors or acetyltransferase enhancers using cultured cells is also provided.

The invention provides a method of preparing a sirtuin complex, a method for detecting a sirtuin in a sample, and a method of screening for compounds which inhibit the deacetylase activity of a sirtuin. The method includes (a) providing a sirtuin substrate having the formula:(b) providing NAD+ or an NAD+ analog having the formula:and (c) providing a sirtuin, wherein R1-R4, A1, A2, and n are as defined herein.

The invention provides a method of increasing a deacetylated activity of SIRT6 by contacting SIRT6 with an agent that binds SIRT6 and reduces the Km of SIRT6 for a substrate, thereby increasing the deacetylase activity of SIRT6. The invention also provides compounds of the formulas (II) and (III).

The present invention provides a genetically engineered strain CIT 4 for efficient and stable production of L-citrulline. The strain uses Escherichia coli as a host. First, the host lacks the activity of argininosuccinate synthase to block the degradation of L-citrulline. It is arginine succinate; the gene argG encoding Escherichia coli argininosuccinate synthase is also integrated on the host genome, and is controlled by the tryptophan promoter P trp Regulate expression; also make the host lack of acetylornithine deacetylase activity; also integrate the gene argJ of Corynebacterium glutamicum encoding glutamate acetyltransferase on the host genome, so as to strengthen the synthesis of glutamate Metabolic flux in the process of acetylglutamate; also integrated on the host genome the genes pyrAA and pyrAB encoding the two subunits of carbamoyl phosphate synthase in the Bacillus subtilis mutant strain A260 to release arginine for carbamoyl phosphate Feedback inhibition of synthetases increases the supply of the precursor carbamoyl phosphate.

A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase / N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof.

In one embodiment, the present invention provides methods of modulating the deacetylase activity of SIRT1 in one or more cell by modifying the binding affinity of lamin A to SIRT1 via one or more interaction modifying compound. In another embodiment, the present invention provides methods of screening SIRT1-activating / inhibiting compounds based on the interaction between lamin A and SIRT1 proteins and SIRT1-activating property of lamin A. In another embodiment, the present invention provides uses of SIRT1-activating compounds to treat patient(s) suffering from metabolic and / or aging-related degenerative diseases, and uses of SIRT1-inhibiting compounds to treat human malignancies.

The present invention screens out several unknown proteins by analyzing and researching different genome sequences of different species, and further identifies a chitin deacetylase with excellent deacetylase activity. More specifically, the present invention relates to a A chitin deacetylase derived from Verticillium longisporum Vlo. Compared with the reported chitin deacetylase, the chitin deacetylase requires less production conditions and has higher biosafety properties, and has characteristics more suitable for industrial applications, showing a wide range of application potential.